Inlyta Articles
Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders
27 March 2013
European approval for Pfizer's kidney cancer drug Inlyta
5 September 2012
FDA OKs Pfizer’s Inlyta and accepts NDA for bosutinib
30 January 2012
Showing 1-7 of 7 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
